Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. by Tsui, Dana Wai Yi et al.
Research Article
Dynamics of multiple resistance mechanisms in
plasma DNA during EGFR-targeted therapies
in non-small cell lung cancer
Dana Wai Yi Tsui1,2,§,† , Muhammed Murtaza1,2,3,†,¶,††, Alvin Seng Cheong Wong4, Oscar M Rueda1,2,
Christopher G Smith1,2, Dineika Chandrananda1,2, Ross A Soo4,5, Hong Liang Lim6, Boon Cher Goh4,5,
Carlos Caldas1,2,3,7, Tim Forshew1,2,‡‡, Davina Gale1,2, Wei Liu1,2,§§, James Morris1,2,
Francesco Marass1,2,¶¶,†††, Tim Eisen3,7,8, Tan Min Chin4,5,9,‡,* & Nitzan Rosenfeld1,2,‡,**
Abstract
Tumour heterogeneity leads to the development of multiple
resistance mechanisms during targeted therapies. Identifying
the dominant driver(s) is critical for treatment decision. We stud-
ied the relative dynamics of multiple oncogenic drivers in
longitudinal plasma of 50 EGFR-mutant non-small-cell lung
cancer patients receiving gefitinib and hydroxychloroquine. We
performed digital PCR and targeted sequencing on samples from
all patients and shallow whole-genome sequencing on samples
from three patients who underwent histological transformation
to small-cell lung cancer. In 43 patients with known EGFR muta-
tions from tumour, we identified them accurately in plasma of
41 patients (95%, 41/43). We also found additional mutations,
including EGFR T790M (31/50, 62%), TP53 (23/50, 46%), PIK3CA (7/
50, 14%) and PTEN (4/50, 8%). Patients with both TP53 and EGFR
mutations before treatment had worse overall survival than
those with only EGFR. Patients who progressed without T790M
had worse PFS during TKI continuation and developed alterna-
tive alterations, including small-cell lung cancer-associated copy
number changes and TP53 mutations, that tracked subsequent
treatment responses. Longitudinal plasma analysis can help
identify dominant resistance mechanisms, including non-drug-
gable genetic information that may guide clinical management.
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Introduction
Molecularly targeted therapies offer substantial clinical benefit in a
subset of patients whose tumours harbour specific oncogenic
drivers. Unfortunately, treatment resistance inevitably develops,
partly driven by the evolving genetic landscape of cancer cells. For
example, though non-small-cell lung cancer (NSCLC) patients carry-
ing activating mutations in EGFR (epidermal growth factor receptor)
initially respond to EGFR-targeted tyrosine kinase inhibitors (EGFR-
TKIs; Lynch et al, 2004; Paez et al, 2004), the emergence of
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mutations that confer resistance to these TKIs or activate alternative
drivers (such as EGFR T790M, MET/HER2 amplifications, PIK3CA
mutation) leads to eventual drug resistance (Yu et al, 2013; Camidge
et al, 2014). Some of these resistance mechanisms are targetable,
such as T790M (Janne et al, 2015; Sequist et al, 2015) and MET
amplification (Sierra & Tsao, 2011). Apart from such individual
genetic changes, a small subset of EGFR-mutant NSCLC patients
develop resistance to EGFR-TKI therapy by undergoing histological
transformation to small-cell lung cancer (SCLC) and become sensi-
tive to standard SCLC treatment (Sequist et al, 2011; Niederst et al,
2015). Therefore, longitudinal monitoring of the dynamic genetic
changes during the course of a patient’s treatment has become
increasingly important to guide treatment at progression or when
resistance occurs. Plasma circulating tumour DNA (ctDNA) is a non-
invasive method that has been used to identify EGFR mutations and
other genetic drivers in NSCLC and in response to treatment of
NSCLC patients with EGFR-TKIs (Yung et al, 2009; Couraud et al,
2014; Douillard et al, 2014; Newman et al, 2014, 2016; Weber et al,
2014; Paweletz et al, 2015; Wan et al, 2017). During treatment of
NSCLC patients with first-generation EGFR-TKIs, serial assessment of
EGFR mutations in plasma ctDNA has proved successful in allowing
early detection of T790M-driven resistance prior to radiographic
progression (Oxnard et al, 2014; Mok et al, 2015). However, a subset
of the patients develop resistance that is independent of the EGFR
pathway, and multiple resistance mechanisms may co-exist because
of tumour heterogeneity (Sequist et al, 2015; Abbosh et al, 2017).
Here, we performed longitudinal analysis of plasma ctDNA to study
the dynamics of co-existing multiple resistance mechanisms during
sequential therapy in NSCLC patients.
In this study, we analysed a cohort of 392 plasma samples
collected longitudinally from 50 Stage IV NSCLC patients. All were
treated with the first-generation TKI gefitinib in combination with
hydroxychloroquine as part of the “Hydroxychloroquine and Gefitinib
to Treat Lung Cancer” trial (NCT00809237). Thirty-four patients were
TKI-naı¨ve (i.e. not previously treated with EGFR-TKI), and 16 were
TKI-treated (i.e. previously treated with TKI with a 2-week washout
period). Eligibility for the trial and patient characteristics are summa-
rized in the Appendix Supplementary Methods. This is a phase II
study with a phase I lead in that studies the tolerability, safety profile
and efficacy of hydroxychloroquine and gefitinib in advanced non-
small-cell lung cancer. Appendix Fig S1 summarizes the number of
patients in each arm (Appendix Fig S1). We performed tagged-
amplicon deep sequencing (TAm-Seq; Forshew et al, 2012) for de
novo identification and quantification of mutations in EGFR exons 18–
21, coding regions of TP53 and PTEN, and selected hotspot regions of
PIK3CA, KRAS and BRAF; and digital PCR for detection and quan-
tification of hotspot mutations in EGFR. For a subset of patients, we
also performed shallow whole-genome sequencing to analyse global
copy number changes during treatment (Heitzer et al, 2013).
Results
Mutational profiling by plasma DNA
To determine whether plasma was a good surrogate of EGFR muta-
tion status in the tumour, we compared the EGFR mutation status in
plasma samples (as determined by our assays) with the tumour
status reported in hospital records. The EGFR status was known in
the tumour of 43 of the 50 patients, and we detected the same EGFR
mutation in any follow-up plasma samples of 41 of 43 (95%)
patients (Fig 1A and Appendix Table S1). In the remaining seven
patients, two were found to be EGFR wild-type in both tumour and
plasma, and the remaining five have EGFR mutations detected in
plasma. In 24 patients who responded to the treatment within the
initial 70 days, 19 of them showed a drop in EGFR cfDNA levels
within that period (Appendix Fig S2 and Appendix Table S2). In
addition to EGFR, somatic mutations in other cancer genes, such as
in TP53 or the PI3K/AKT/mTOR pathway (PIK3CA and PTEN), were
also identified in the plasma of 29 patients (Fig 1B). Of the identified
mutations, 25–43% are likely oncogenic (TP53, 10/23, 43%;
PIK3CA, 3/7, 43%; PTEN, 1/4, 25%) according to OncoKB annota-
tion (Chakravarty et al, 2017). To further compare molecular pro-
files between tumour and plasma, we studied paired tumour and
plasma samples in four patients, where tumour samples were avail-
able before and after disease progression. The types of EGFR muta-
tions identified in plasma and tumour (EGFR activating, resistance-
conferring mutations in EGFR and other mutations) were identical
for 11 of 12 (92%) mutations before treatment, and for 9
of 12 (75%) mutations after treatment (Appendix Fig S3 and
Appendix Table S3). Plasma captured the same or more mutations
than tumour in 23 of 24 cases (96%). These results confirmed that
plasma analysis is informative for mutation profiling in NSCLC
patients using our assays. Initial changes in EGFR ctDNA levels after
start of treatment mirrored in most cases the radiographic assess-
ment of clinical response.
Prognostic value of baseline plasma DNA
We studied the relationship between pre-treatment EGFR ctDNA
levels and prognosis in 19 TKI-naı¨ve patients (Appendix Table S4),
for which at least one plasma sample was collected before initiation
of treatment. Patients with low levels of EGFR-activating mutations
pre-treatment tended to have better progression-free survival (PFS)
and overall survival (OS; Fig 2A and B), though this did not reach
statistical significance level of 0.05 (their corresponding Cox
P-values were 0.06 for both PFS and OS). Of note, patients with low
levels of EGFR-activating mutation allele fractions had reduced
tumour burden (median 17 mm) by RECIST measurements, as
compared to those with intermediate (median 42 mm) and
high (median 80 mm) levels of EGFR-activating mutation
(Appendix Table S4). These findings suggest that baseline mutation
concentrations in the plasma correlate with tumour burden. In addi-
tion, patients with both EGFR and TP53 detected in pre-treatment
plasma tended to have worse prognosis (Fig 2C and D, Cox P-value
0.109 for PFS and 0.035 for OS). We repeated the analysis with
copies/ml instead of mutant allele fractions, and the conclusions
were the same. These data suggest that both the molecular profile of
genomic alterations, and the quantification of ctDNA levels in base-
line plasma, can have prognostic implications.
Mutation dynamics in plasma DNA reveals heterogeneous
resistance mechanisms
For 45 of 50 patients, EGFR mutations were detected before treat-
ment in tumour and/or plasma and more than one plasma sample
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was available from clinical follow-up. Longitudinal analysis of
ctDNA in plasma revealed heterogeneity of resistance mechanisms
(Fig 3A). During longitudinal follow-up, a large subset of patients
retained the sensitizing mutation and developed resistance-confer-
ring EGFR T790M mutation (n = 28/45, 62%, Fig 3B). To estimate
the detection lead time (i.e. the interval between detection of the
resistance-conferring mutation in plasma and radiographic evidence
of disease progression), we focus on 28 patients where T790M was
detected in plasma at any time during EGFR-TKI, including detection
before disease progression became evident. In patients treated with
first-line EGFR-TKI, we found that the median time-to-appearance of
T790M in plasma was 4 months from the start of TKI treatment,
with a lead time between T790M detection and clinical progression
of 6.8 months. Patients with EGFR T790M can now be treated with
third-generation, irreversible EGFR-TKIs (Janne et al, 2015;
Piotrowska et al, 2015). One patient (220) had a biopsy of the lung
tumour after progression, in which both activating EGFR exon 19
and T790M mutations were detected. The same mutations were
detected in plasma at the time of progression. This patient was then
treated with a third-generation EGFR-TKI (EGF-816, Novartis
(NCT02108964)) and demonstrated partial radiological response.
Subsequent plasma samples showed no further EGFR mutations
(data shown in Dataset EV1).
In a second group of patients (n = 10/45, 22%), the activating
EGFR mutation was detected in plasma before and after progres-
sion, with an average mutant allele fraction (AF, i.e. the fractional
concentration of mutant allele over total DNA) of 7.9%, but not
T790M (Fig 3C). The continued presence of activating mutations
in plasma suggests possible positive selection of the mutations in
the EGFR pathway in the corresponding cancers. In these patients,
mutations in other pathways also emerged in plasma, such as
TP53 and PIK3CA (Dataset EV1). One possible hypothesis is that
tumours of patients in this group may retain partial sensitivity to
EGFR-TKI treatment, and may respond clinically if EGFR-TKI is
used in combination with treatments targeting additional resistance
pathway.
The third group of patients (n = 7/45, 15%) did not have EGFR-
activating nor known resistance-conferring mutations in EGFR
detected in plasma when they progressed. These patients initially
had exon 19 deletion detected in the tumour (7/7) and their first
plasma sample (6/7). Interestingly, comparing to the other two
groups, this group of patients had EGFR-activating mutations
A
B  Summary of mutations detected in longitudinal plasma of the 50 patients
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Figure 1. Summary of somatic mutations identified in the 50 NSCLC patients.
A Detection of tumour EGFR mutations in plasma. EGFR mutation status in tumour samples was documented in the clinical record for 43 patients (Appendix Table S1),
of which 38 had verified hotspot activating mutations (deletion in exon 19 for 23 patients and the L858R mutation for 15 patients), three patients had other
mutations in EGFR (one of these patients had two different mutations detected in the tumour sample), and two patients were wild-type for EGFR according to tumour
analysis and confirmed by plasma analysis.
B Summary of the mutations identified in any of the plasma samples during longitudinal follow-up in the 50 patients. TKI-naïve (n = 34) and TKI-treated (n = 16)
patients are presented separately.
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present at relatively lower allele fractions in their first plasma
samples [groups 1 and 2: median EGFR mutations mutant allele
fractions was 3% (range: 0.07–65.7%) versus group 3: median
0.23% (range: 0.06–2.11%)]. We do not rule out the possibility that
the tumours of these patients might release less tumour-derived
DNA into the circulation. In some of these patients, we detected
alternative cancer mutations such as TP53 and PIK3CA in plasma
before treatment was initiated, and the levels of these mutations
then increased to present the highest allele fractions in ctDNA when
disease progressed (Fig 3D). We speculate that one possible
explanation for the absence of EGFR mutations in cfDNA at disease
progression could be that, EGFR mutations were subclonal in those
patients initially, and under the selective pressure of the EGFR-
targeting therapy, the EGFR-driven clones shrank below detection
limit of the assay, while clones that were driven by alterative
drivers (such as TP53 and PIK3CA) and did not carry the EGFR-
sensitizing mutations, expanded. Based on our data from cfDNA,
these alternative drivers pre-existed even before treatment initia-
tion, but were present in parts of the tumour that were not anal-
ysed, or alternatively were present at very low cellularity such that
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Figure 2. Prognostic value of qualitative and quantitative assessments of pre-treatment ctDNA.
A, B The relationship of pre-treatment EGFR-activating mutation levels (allele fractions) with progression-free survival (PFS) and overall survival (OS) of 19 first-line
TKI-treated patients where baseline plasma samples (collected before the start of treatment) were available. Patients were grouped into three groups according to
their pre-treatment ctDNA levels, as measured by EGFR-activating mutation allele fractions: low (< 25% quartile), intermediate (25–75% quartile) and high (> 75%
quartile) ctDNA levels. Kaplan–Meier survival curves indicated that patients with high baseline pre-treatment EGFR-activating mutant allele fractions were non-
significantly associated with unfavourable (A) PFS (log-rank P-value = 0.11) and (B) OS (log-rank P-value = 0.16), Cox P-value of 0.06 for either PFS or OS.
C, D The prognostic value of concurrent TP53 and EGFR mutations in pre-treatment plasma samples before EGFR-TKI therapy. This analysis was performed in 30 first-
line EGFR-TKI patients where plasma samples were available within 2 months of start of treatment. The presence of both TP53 and EGFR mutations in plasma was
associated with a trend of worse PFS (log-rank P-value = 0.109, hazard ratio and 95% confidence interval: 0.53 [0.24–1.17]) and significantly worse OS (log-rank
P-value = 0.035, hazard ratio and 95% confidence interval: 0.43 [0.20–0.97]).
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their allele fractions in those samples were below the detection
limit by standard clinical tumour sequencing assay. Recent data
from tumour sequencing suggested EGFR may be subclonal in a
small subset of EGFR-mutant NSCLC tumour (McGranahan et al,
2015), which agrees with our hypothesis. A recent plasma-based
study also reported 4 out of 24 NSCLC patients had EGFR-sensi-
tizing mutations detected in plasma at T0 but absent when the
patients progressed, which agreed with our findings (Pecuchet
et al, 2016). The fact that EGFR T790M was not detected in the
third group suggested that the cancers have developed resistance
mechanisms that are alterative to the EGFR pathway, which agreed
with the observations of alternative drivers in plasma in some
patients. For the patients whom we did not detect T790M nor other
drivers were detected, they may have progressed due to other resis-
tance mechanisms that were not covered by our targeted sequenc-
ing assay.
Of note, overall, TKI-naı¨ve patients who progressed without
T790M detection (13 patients selected from the second and the third
groups) had a significantly worse PFS (Appendix Fig S4A and
Appendix Table S5, P-value = 0.008), and a trend towards worse OS
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Figure 3. Longitudinal analysis of ctDNA dynamics reveals distinct patterns of resistance mechanisms.
A Longitudinal analysis of ctDNA dynamics in 45 NSCLC patients revealed three main groups of concurrent heterogeneous resistance mechanisms.
B In the first group (n = 28/45, 62%), patients retained EGFR-sensitizing mutations before and after disease progression, with the development of T790M in their
plasma samples, indicating that at least some of the progressing clones developed resistance to TKI by acquiring T790M.
C In the second group (n = 10/45, 22%), patients retained EGFR-sensitizing mutations but progressed without developing T790M in their plasma samples, suggesting
that resistance arose due to other mechanisms which were not analysed in this dataset.
D In the third group (n = 7/45, 15%), patients progressed without EGFR-sensitizing nor resistance-conferring T790M mutations detected in their plasma samples.
Resistance possibly develops through dependence on alternative cancer driver pathways.
Data information: For patients where multiple EGFR-activating mutations were identified in plasma, only the most abundant one is shown here (complete data for all
patients are shown in Dataset EV1). Clinical progression and CT imaging times are indicated with a dotted line, with RECIST classification: SD, stable disease; PR, partial
response; PD, progressive disease. Progressive disease defined by presentation of symptoms on brain or bone scan is indicated by PD**.
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(Appendix Fig S4B, P-value = 0.22), as compared to T790M-positive
patients. These observations confirm results from a re-biopsy study
(Oxnard et al, 2011), suggesting that patients that progress without
T790M are less likely to benefit from TKI continuation, possibly due
to the more aggressive nature of their disease or reduced depen-
dency on the EGFR pathway.
Dynamics of EGFR mutations in plasma across multiple lines
of treatment
To explore the utility of monitoring both activating and resis-
tance-conferring mutations, we investigated their relative repre-
sentation in plasma in relation to radiographic assessment in one
patient for whom samples were available spanning sequential
lines of first-generation EGFR-TKI and chemotherapy (Fig 4).
Three lesions were tracked by imaging (Fig 4B): in the lung (L1),
left liver lobe (L2) and right liver lobe (L3). During treatment with
TKI, all three lesions initially shrank, before a small incremental
increase in the size of L3 from day 49, although this did not
amount to RECIST progression. The mutant AF of EGFR-activating
mutation (exon 19 deletion) decreased initially but increased
from day 134 (Fig 4A). The T790M mutation was detected from
day 189.
On day 297, L3 showed a substantial growth. The T790M muta-
tion at that timepoint reached AF of 3.6%. Treatment was changed
to platinum-based doublet chemotherapy at which point L3 showed
a reduction on serial CT imaging, which coincided with a drop of
the T790M mutation AF to 0.7% (Fig 4A). At day 679, despite the
shrinkage of L3, L1 and L2 grew, coinciding with an increase in the
AF of the activating mutation from 8.6% (when responding to initial
TKI) to 43%. The patient was given a first-generation EGFR-TKI re-
challenge (newer TKIs were not yet approved at the time this patient
was treated), and activating mutation sharply dropped back to
6.4%, corresponding to a reduction in L1 and L2.
From day 217 to 244, both EGFR mutations exhibited a sharp
drop in AF in plasma, for reasons we do not understand, and may
be related to metabolic effects or technical artefacts. The increased
AFs from days 244 to 272 may be a related transient effect. Simi-
larly, the sample collected on day 300 from patient 103 presented an
unexpectedly low total cfDNA level (> 10-fold different from the
timepoint immediately before and after), which could potentially
influence the interpretation of mutant allele fractions at that time-
point. Such variations could be contributed by effects of processing,
collection or other technical reasons. We have therefore excluded
that timepoint from the analysis. To normalize for these kinds of
pre-analytic effects, and to explore the relative representation of the
alleles, we calculated the ratio of AFs of the resistance-conferring/
activating EGFR mutations (Fig 4A). The ratio was zero before the
start of TKI. It reached a maximal value of 0.43 during first-line TKI
(when L3 grew substantially), dropped to 0.02 after chemotherapy
(corresponding to a reduction in L3), then rapidly increased upon
TKI re-challenge to 0.67.
A ChemoTKI TKI
Tu
m
ou
r l
es
io
n 
si
ze
 (m
m
)
Ra
tio
 o
f r
es
is
ta
nt
 to
 
ac
tiv
at
in
g 
m
ut
at
io
ns
200 400 600 8000
M
ut
an
t a
lle
le
 fr
ac
tio
n 
(%
)
0 200 400 600 800
0
10
20
30
40
0
10
20
30
40
0
10
20
30
40
PR PD PD
0 200 400 600 800
0
0.
1
1
Days from start of treatment
EGFR activating mutation
EGFR resistance-conferring mutation 
*Treatment discontinued and switched to supportive care.
*
N
D
0.
1
1
10
10
0
Lung lesions
Left lobe liver lesion
Day 0 Day 297 Day 679 Day 741
Right lobe liver lesion
B
(i)
(ii)
(iii)
(i)
(ii)
(iii)
Figure 4. Analysis of relative representation of activating and resistance-conferring mutations in EGFR during sequential therapy.
A (i) Sizes of three different lesions in patient 103 over time, measured from the start of first-line TKI treatment. Shading indicates duration of treatment with TKI (days
0–297), chemotherapy (days 297–679), and TKI re-challenge (days 679–783). From day 783, the patient was treated with supportive care. Dotted lines indicate the CT
imaging assessment at select timepoints. (ii) Levels of activating EGFR mutations (exon 19 deletion) and resistance-conferring EGFR T790M mutations for patient 103
(Dataset EV1). (iii) Ratio of resistance-conferring/activating mutations, calculated from data shown in Appendix Table S1 (excluding the data at T = 300 days).
B CT imaging scans performed at the start of TKI treatment (day 0), at the change of treatment to chemotherapy (day 297), at the end of chemotherapy and start of TKI
re-challenge (day 679), and after initiating TKI re-challenge (day 741). Sizes are assessed from CT imaging scans, and indicated by blue (i, lung), green (ii, left lobe
liver) and orange (iii, right lobe liver) lines. Lesions identified in the lung (blue arrow), left lobe liver (green arrow) and right lobe liver (orange arrow) are indicated. PR,
partial responses; PD, progressive disease.
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Although a liver biopsy was not performed, which may have
been able to confirm the presence of T790M in L3, the clinical and
radiological evidence in conjunction with the dynamics of EGFR
mutations in plasma strongly suggests that the T790M was present
in L3 but not in L1/L2. This suggests that the ratio of resistance-
conferring/activating mutations in plasma can help identify domi-
nant drivers of disease and progression in real time (Oxnard et al,
2016).
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Figure 5. Plasma analysis reveals global copy number changes and ctDNA dynamics in patients who have undergone histological transformation to SCLC
(patient 223).
A CT liver scans are shown: At day 63, the patient had progressed on platinum-based chemotherapy, and CT of the liver showed appearance of new liver lesions. Liver
biopsy at that point confirmed small-cell lung cancer in new lesions in the liver. CT of the liver at day 354 shows marked growth in the liver lesions, after a period of
transient response to cisplatin and irinotecan.
B The timeline of the patient’s treatment is charted, alongside the timepoints where plasma and tumour samples are available for molecular analyses. Per diagram
timeline, tumour samples were available from diagnosis (3 years prior to recruitment for study) (i) and at day 63 (iii). Plasma samples were available at day 0 (ii) and
day 354 (iv). The mutations allele fractions for TP53 and PIK3CA are shown.
C Global copy number profiles in plasma samples collected prior to small-cell transformation (ii) and after SCLC transformation and progression on cisplatin and
irinotecan (iv). Global copy number profiles in tumour samples collected at diagnosis of NSCLC (i) and at small-cell transformation (iii). CNA events that were
significantly identified and coincide with literature-reported SCLC events are denoted in colours: blue for gain and orange for loss.
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Copy number changes and mutations detected in plasma after
SCLC transformation
Recent findings have shown that around 2–3% of NSCLC patients
develop resistance to EGFR-targeted therapies by undergoing histo-
logical transformation to small-cell lung cancer (SCLC; Sequist et al,
2011). In our cohort, three patients (patients 122, 223, 218) were
confirmed to present SCLC histology based on re-biopsy examina-
tion at progression. We used targeted deep sequencing and shallow
whole-genome sequencing of plasma DNA to track and study the
dynamics of somatic point mutations and global copy number alter-
ations (CNAs) in samples collected before and after SCLC transfor-
mation in those patients.
T790M mutations were not detected in plasma at disease progres-
sion for any of the three SCLC-transformed patients, and two of
them (patients 122 and 218) retained the EGFR-activating mutations
in plasma after SCLC transformation. TP53 mutations were detected
before EGFR-TKI initiation in all three patients’ baseline plasma
samples, at low levels (< 1%) compared to the EGFR-activating
mutations, and their levels in plasma increased with disease
progression (patient 122, 223) or decreased when patient demon-
strated clinical response (patient 218) during small-cell lung cancer-
directed chemotherapy (Figs 5 and 6, and Appendix Fig S5). Analy-
sis of the plasma samples collected after transformation in all three
patients revealed the emergence of CNAs that have been previously
reported to be associated with SCLC, including MYCL1, SOX2 and
SOX4 (George et al, 2015; Figs 5 and 6, and Appendix Fig S5). In
each patient, we also identified gain or loss of cancer genes as
part of larger chromosomal events (> 5 Mb; Figs 5 and 6, and
Appendix Fig S5). These may have contributed to the biological
change or may represent passenger events as a result of greater
genomic instability of the TP53-mutant clones. We observed focal
copy number changes at key oncogenic drivers that may play a role
in driving disease progression, for example, amplification of KRAS
in patient 223 (Fig 5) and amplification of EGFR in patients 122 and
218 (Appendix Fig S5 and Fig 6).
Patient 223 (Fig 5A) initially harboured an exon 19 activating
EGFR mutation, had indolent disease and remained clinically and
radiologically responsive to first-line EGFR-TKI for 2 years. Subse-
quently, there was development of PET FDG-avid, but subcentime-
tre, liver lesions that were not clearly appreciated on CT imaging. At
this point, even though progression was only obvious in two new
small spots on PET imaging (stable disease by CT and RECIST crite-
ria), ctDNA showed multiple copy number changes (Fig 5B and C,
plasma 1). There was subsequent rapid growth of the liver lesions,
despite two lines of chemotherapy. A liver biopsy was performed at
that point, and showed only small-cell carcinoma, with no further
activating nor T790M EGFR mutations found in the small-cell
cancer. Figure 5C demonstrates that a few months prior to the con-
firmation of small-cell transformation, plasma analysis already
showed marked copy number changes, this time of focal amplifi-
cation of MYCL1 and KRAS, known oncogenic drivers in the KRAS
pathway. These focal genomic changes were also observed in the
subsequent liver biopsy, showing parallel changes in both tumour
and plasma, suggesting that plasma is a good surrogate for study of
genomic copy number alterations and evolution. In this particular
case, the copy number changes were more markedly observed in
the plasma, compared to the tumour, likely due to scarcity of
tumour cells in the repeat biopsy.
Another patient with SCLC transformation (patient 218, Fig 6A)
harboured an EGFR L858R-activating mutation at diagnosis, and
again demonstrated a good clinical and radiological response, with
progression-free survival of 14 months on first-line EGFR-TKI
(Fig 6B). Upon clinical progression while on treatment with EGFR-
TKI (day 78), the plasma analysis (Fig 6B plasma 1) showed
increased levels of EGFR L858R as well as a TP53 R175H mutation,
one of the most frequently observed mutations in TP53. On treat-
ment with platinum-based doublet chemotherapy with pemetrexed,
the patient achieved stability of disease. There was however early
progression on maintenance pemetrexed and despite a switch to
carboplatin and docetaxel, the patient’s lung mass progressed, and a
biopsy confirmed SCLC, harbouring the original activating EGFR
L858R mutation. At this point, the patient was switched to treatment
for SCLC with carboplatin and etoposide, with a radiological
response and corresponding reduction in TP53 R175H mutation
(Fig 6B, plasma 3). Unfortunately, the treatment response was tran-
sient, and there was development of widespread symptomatic
metastases in both the brain and spine, necessitating radiotherapy
to those areas. At the completion of radiotherapy, the patient had
developed liver metastases with rapid progression. At this point, we
observed marked copy number change in plasma 4 and 5 analyses
(Fig 6C and Appendix Fig S6). This example illustrates that dynam-
ics of genomic copy number changes in plasma reflect the muta-
tional burden and radiologic responses.
The losses of TP53 and RB1 are common in SCLC (George et al,
2015), and we therefore attempted to look for RB1 somatic copy
number alterations but did not find any significant signal by sWGS.
In patient 218, RB1 did appear to have a reduced copy number, but
this event could be part of a much larger chromosomal aberration,
and thus, we cannot rule this out as being a passenger event. RB1
▸Figure 6. Plasma analysis reveals global copy number changes and ctDNA dynamics in patients who have undergone histological transformation to SCLC(patient 218).
A CT images of the left lung tumour at baseline (day 730), and upon progression on EGFR-TKI (day 78). The patient was treated for non-small-cell lung cancer from
days 78 to 329 with two lines of chemotherapy: initially carboplatin and pemetrexed, followed by docetaxel. The CT image corresponding to plasma 2 and re-biopsy of
the tumour at day 329 was upon progression on the above two lines of chemotherapy. CT image corresponding to plasma 3 at day 379 was upon response to small-
cell lung cancer chemotherapy. CT corresponding to days 500 and 524 are upon progression on cisplatin and etoposide. Marked growth of the lung and liver lesions
are demonstrated, and this corresponds to marked CNA changes on plasma drawn on those respective days.
B The timeline of the patient’s treatment is shown, alongside timepoints where tumour and plasma samples were available for analyses. The bottom chart shows the
respective mutations that were found, and the changes to the mutation allele fractions in a longitudinal timeline.
C Global copy number profiles in tumour and plasma samples are shown: Tumour samples at baseline diagnosis of non-small-cell lung cancer (day 730) and at
transformation to small-cell lung cancer (day 329). For plasma samples, the following were available: days 78 (upon progression on EGFR-TKI); 329 (at transformation
to small-cell lung cancer); 379 (at response to small-cell lung cancer); 500 and 534 (progression on small-cell lung cancer treatment).
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alterations are important driver in SCLC, but it is not necessarily the
only driver (Karachaliou et al, 2016). All three SCLC-transformed
patients have evidence of TP53 mutations in their SCLC re-biopsies,
and pre- and post-transformation plasma suggest that TP53 is an
important driver in these particular patients.
In all three patients, CNAs were more evident in plasma as
compared to tumour DNA analysis, likely due to scarcity of tumour
cells at repeat biopsy. The data also illustrate that the global CNA
profile in plasma can act as an indicator of disease burden and can
be used to track clinical progression, as previously suggested in
other cancer types (Heitzer et al, 2013). Subtype-specific mutational
and CNA signatures can be identified in plasma in association with
histological transformation that warrants different treatment strat-
egy, and their increasing levels in plasma can pre-date radiological
progression (by CT imaging). These observations suggest that
plasma genomic changes could be indicative of early progression,
and may complement current imaging modalities in monitoring
response.
Discussion
We studied the dynamics of concurrent somatic point mutations
and copy number alterations in plasma DNA during treatment of
NSCLC patients with EGFR inhibitor. Several observations may
provide information for the design of future plasma DNA studies of
patients treated with targeted therapies:
First, we found a strong concordance between EGFR status in
tumour and plasma samples, and showed that mutations in multiple
cancer-related genes can be identified directly in plasma by targeted
sequencing. These results confirm findings from a previous valida-
tion study (Douillard et al, 2014; Weber et al, 2014; Huang et al,
2017), and lend further credibility to the application of circulating
DNA in plasma for non-invasive molecular profiling and treatment
stratification (Jamal-Hanjani et al, 2017; Remon et al, 2017).
Second, high pre-treatment levels of ctDNA, and specifically of EGFR
mutations in plasma prior to treatment with EGFR-TKI, correlated
with increased tumour burden and were associated with poor prog-
nosis, echoing previous findings (Mok et al, 2015). We also showed
that early changes in levels of ctDNA (in our case, of EGFR muta-
tions) may predict initial response (Parkinson et al, 2016). Both of
these findings lend support to the analysis of baseline and subse-
quent plasma samples for EGFR mutations to track treatment
responses. Third, we detected the emergence of the T790M mutation
in approximately 50% of patients who progressed on TKI, at a
median of 6.8 months before clinical progression. Early identifi-
cation of emerging resistance highlights the potential to use ctDNA
to guide clinical interventions such as therapies that target T790M-
mutant cells (Janne et al, 2015; Sequist et al, 2015; Chabon et al,
2016; Remon et al, 2017).
In addition, we showed that profiling TP53 in plasma before
EGFR-targeted therapy can provide prognostic value. Cancers
harbouring both TP53 and EGFR mutations in baseline plasma were
associated with inferior overall survival in patients treated with
EGFR-targeted TKI. This confirmed observations from a tumour
sequencing study (Labbe et al, 2017), and because plasma DNA
captures the mutations coming from different parts of the tumour,
we found that in some patients, these TP53 mutations pre-existed at
AF < 1% in plasma prior to treatment and later became the domi-
nant mutations in plasma when patients progressed or exhibited
histological transformation to SCLC. This echoes one of the recent
findings that EGFR-TKI-resistant SCLCs can branch out from early
events that pre-existed in NSCLC prior to transformation based on
tumour biopsy analysis (Lee et al, 2017).
These data highlight the potential value for clinical management
of analysing mutations which may not be perceived as “actionable”,
such as mutations in the tumour suppressor TP53, and suggests that
the genetic context of an EGFR-mutant tumour may determine its
dependence on the EGFR and/or other pathways and predict sensi-
tivity or resistance to EGFR-directed treatment. Tracking the dynam-
ics of multiple mutations showed that different resistance
mechanisms co-existed, and are likely to be the result of tumour
heterogeneity (Piotrowska et al, 2015). As illustrated by the above
clinical cases, the response and progression of different lesions coin-
cided with the changing levels of distinct mutations in plasma. As
treatment selection pressure is dynamic, analysing the relative
proportions of different oncogenic drivers in plasma at any one
point may provide insight on a particular dominant oncogenic path-
way dependence and guide decisions on subsequent treatment by
targeting the current dominant clone.
Finally, we showed that tracking the dynamics of plasma EGFR
mutations alone may not provide the most accurate estimate of
tumour responses, as seen in the 14% of patients who progressed
with decreasing levels of EGFR mutations in plasma. We speculate
that this observation may be explained by the recent finding of
subclonal EGFR driver mutations in 3 of 21 (14%) NSCLC cases
(McGranahan et al, 2015), and suggest that monitoring EGFR-
targeted therapies by ctDNA would require tracking mutations
beyond EGFR. These findings will need to be confirmed by further
studies in larger cohorts. Nonetheless, using a multi-gene assay, our
data revealed the presence of concurrent oncogenic drivers before
treatment. Parallel analysis of somatic point mutations and global
CNA events (by shallow WGS) could more accurately track disease
burden and detect subtype-specific events (e.g. marked copy
number changes associated with histological transformation). In
particular, we identified multiple genomic changes in the plasma of
three patients who underwent transformation to SCLC (patients 122,
223 and 218), which correlated closely with burden of disease. All
three patients presented increasing fractions of TP53 mutations that
pre-existed at < 1% levels in plasma before treatment, together with
recurrent SCLC CNA events in ctDNA at the time of transformation.
These changes correlated closely with burden of disease, and CNA
signals in plasma reduced accordingly when computerized tomogra-
phy imaging showed radiological response to chemotherapy. In
these cases, it was interesting to note that all cases exhibited dif-
ferent drivers, TP53 in the first case, MYCL-1 and KRAS in the
second, and two TP53 mutations in the third. It may be that each
patient has a unique signature of genomic copy number change that
may reflect disease burden, and this can be used to determine
responding or progressive disease at various timepoints, with rela-
tion to each line of treatment received. However, the complex and
varied genomic landscape in these transformed small-cell lung
cancers underscores the difficulty in targeting any one of these
genomic signatures (even if actionable), and providing support for
the use of chemotherapy, which is currently the most appropriate
treatment for targeting these multiple genomic instabilities. Our
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findings suggest that an observation of multiple genomic copy
number changes in the plasma of a patient with rapid progression of
disease on EGFR-TKI should prompt the need to re-biopsy to exclude
the possibility of small-cell transformation. To date, EGFR T790M
remains the main actionable resistance mechanisms in the context of
EGFR-TKI. However, the ability to reveal TP53 mutations or other
possible SCLC-associated genomic signatures in plasma would
provide additional insight into possible resistance mechanisms that
are particularly important in individuals that show no evidence of
T790M or other known resistance mechanisms, and may justify the
need for a re-biopsy to confirm the histological transformation.
Our study, spanning 392 clinical samples analysed by a combina-
tion of genomic techniques, describes multiple genomic changes in
EGFR-mutant patients with acquired resistance to first-generation
EGFR-TKIs, and may explain the heterogeneity of treatment
response to EGFR-TKIs in EGFR-mutant patients with similar activat-
ing mutations. We studied key genomic driver events of lung
cancer, and evaluated their significance in a temporal and dynamic
way with respect to disease response and progression in patients
with analyses of longitudinal plasma studies. As the majority of
patients were treated when second- and third-generation EGFR-TKIs
were not readily available, most patients with acquired EGFR
T790M mutation were not routinely re-biopsied and were treated
with chemotherapy. Analyses of changes in ctDNA in response to
treatment with second- and third-generation EGFR-TKIs are not
within the scope of this study. Nonetheless, some of the acquired
resistance mechanisms described here may also apply to acquired
resistance to a wide range of EGFR-TKIs. Importantly, our study
represents the first report on ctDNA changes in EGFR-mutant
cancers before and after histological transformation to SCLC and
provides important insight into the management of this alterative
form of resistance mechanism to EGFR-TKI.
In summary, our data show that in the NSCLC EGFR-targeted
therapy setting, analysing the presence and dynamics of both
actionable oncogenic drivers (such as EGFR mutations) and
other, potentially “non-actionable” alterations (such as TP53
mutations and global copy number changes), before and during
treatment, can offer clinically relevant information to potentially
guide subsequent clinical management.
Materials and Methods
Sample collection and processing
Patients with metastatic NSCLC treated by gefitinib in combination
with hydroxychloroquine therapy attending the University Hospital
of Singapore, Singapore, during January 2009 to May 2014 were
recruited as part of the “Hydroxychloroquine and Gefitinib to Treat
Lung Cancer” study (NCT00809237). This was a single-arm phase II
study that recruited two groups of patients. In the first group, EGFR-
TKI-naive patients who were known to have activating EGFR muta-
tions were recruited to determine whether hydroxychloroquine
improved the efficacy of gefitinib. The second group included
patients who had previously responded to EGFR-TKIs for at least
12 weeks (per Jackman criteria for acquired resistance to EGFR-
TKI) and aimed to determine whether the addition of hydroxy-
chloroquine to gefitinib would reverse acquired resistance in these
patients. Please see consort diagram (Appendix Fig S1) for further
details including number of patients in each arm included for the
purpose of this cDNA study (note that this represents a subset of the
original clinical study—as this was subject to availability of plasma
samples). Blood was collected from patients in a CPT sodium citrate
tube (BD) every 4 weeks and stored at 80°C. CT imaging of rele-
vant measurable sites of disease was performed every 8 weeks. This
study was approved by the Singapore National Healthcare Group
(Singapore National Healthcare Group Domain Specific Review
Board NHG DSRB Reference: 2008/00196). Blood and tumor collec-
tion were also collected and approved by NHG DSRB 2014/00131.
Informed consent has been obtained from all patients involved in
this study. DNA was extracted from 0.8 to 2 ml of plasma using the
Qiagen QIAamp Circulating Nucleic Acid Kit (Qiagen) and eluted
into 50 ll buffer AVE. More details of sample processing are given
in Appendix Supplementary Methods. A spike-in control, non-
human DNA PCR product was added to the lysis buffer during DNA
extraction to control for extraction efficiency.
Mutation identification and quantification by TAm-Seq and
digital PCR
Analysis by tagged-amplicon deep sequencing (TAm-Seq) was
performed using the panel described previously (Forshew et al,
2012), with the addition of an amplicon that covers exon 18 of EGFR
(additional details in Appendix Supplementary Methods). All
samples were analysed by at least two replicates to control for errors
arising during PCR. The purified libraries were sequenced using
paired-end 100 bp read length of a HiSeq 2000 or HiSeq 2500 System
(Illumina, USA). Somatic mutations were identified based on filtering
against the matched normal control (white blood cells) of the same
patient. For quantification of known hotspot mutations in EGFR,
namely exon 19 deletion, T790M and L858R, digital PCR analysis
was developed and optimized: sensitivity and specificity and limit of
detection was determined using samples with known mutations and
samples from healthy volunteer controls (Appendix Fig S7 and
Appendix Table S6). Assays were performed using the BioMark
system using 12.765 Digital Arrays (Fluidigm, USA) following manu-
facturer’s instructions and protocol. Total DNA levels (amplifiable
copies per ml) were also quantified in every plasma sample by digital
PCR using a 65-bp assay targeting a region on the RPP30 gene
(Appendix Table S7), a region in the genome that is not amplified in
lung cancer (Wang et al, 2010). Two samples were excluded from
analysis due to an unexplained sharp drop in total circulating DNA
levels extracted from plasma, with >10-fold drop in those levels
compared to samples collected few weeks prior and no evident asso-
ciation with any clinical or treatment parameters. This is suspected
to be related to technical fault either at collection or processing of
samples. Evaluation of the specificity and sensitivity of the assays
was described in Appendix Supplementary Methods. The primer and
probe sequences of all the digital PCR assays are summarized in
Appendix Table S7. The mutant allele fractions measured by TAM-
Seq and ddPCR strongly correlate with each other (Appendix Fig S8).
Shallow whole-genome sequencing (sWGS)
Libraries were prepared from either plasma DNA (5–10 ng), sheared
tumour DNA, or sheared buffy coat DNA using the Plasma-Seq
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protocol (Rubicon, USA). Briefly, end repair and “A-tailing” of frag-
ment ends preceded the ligation of truncated Illumina sequencer-
compatible adapters to fragment ends. Thermocycling of libraries
completed the adapters through the addition of sample-specific index
sequences, and was performed as described in the Plasma-Seq proto-
col (Heitzer et al, 2013), using 10 (plasma) or 8 (tumour and buffy
coat) amplification cycles. Upon amplification libraries were cleaned
using Agencourt AMPure XP beads (Beckman Coulter, USA) at a 1:1
(v/v) ratio and eluted in 30 ll nuclease-free water. Successful library
preparation was confirmed by running 1 ll of library on a High-
Sensitivity Bioanalyser gel, and libraries were quantified using SYBR-
green-based qPCR (Kapa Biosystems, USA). Libraries were pooled in
an equimolar fashion, and 125-bp paired-end sequencing was
performed on Illumina sequencers (Illumina, USA).
Paired-end sequence reads were aligned to the human reference
genome (GRCh37) using BWA, SAMtools was used to convert files to
BAM format, to which mate pair information was added. PCR dupli-
cates were marked using Picard-Tools’ “MarkDuplicates” feature and
were excluded from downstream analysis. Fragment lengths were
analysed using Picard-Tools’ “CollectInsertSizeMetrics”. CNA calling
was performed in R using the program QDNAseq (Scheinin et al,
2014). Briefly, sequence reads were allocated into equally sized (here
1 Mb and 50-kb bins) non-overlapping bins throughout the length of
the genome. Read counts in each bin were corrected to account for
sequence GC content and mappability, and regions corresponding to
previously “blacklisted” regions (ENCODE) were excluded from
downstream analysis. Within the QDNAseq package, bins were
segmented using the “Circular Binary Segmentation” algorithm
(Venkatraman & Olshen, 2007) and significantly “amplified” or “lost”
regions were called using CGHcall (van de Wiel et al, 2007).
Data deposition
Sequence data have been deposited at the European Genome-
phenome Archive (EGA), which is hosted by the EBI and the CRG,
under Accession no. EGAS00001002908.
Survival analysis
Kaplan–Meier curves were computed for prognostic groups defined
by their mutation fractions, and log-rank tests were computed for
testing differences in survival. We measured pre-treatment ctDNA
levels using allele fractions of the EGFR-activating mutations and
computed Kaplan–Meier survival curves to evaluate the effects of
different levels of pre-treatment ctDNA: We divided patients into
three groups: low pre-treatment ctDNA levels (less than the lower
quartile), intermediate (second and third quartiles) or high (upper
quartile). All survival analyses were performed using the R package
survival (Therneau, 2012). It should be noted that only the EGFR-
TKI-naı¨ve group of patients with available pre-treatment plasma
samples (n = 19) were used for progression-free and overall
survival analyses, and correlative prognostic study. This is to ensure
analyses of a homogeneous population. The survival analyses of
both groups of patients will be reported in a separate clinical paper
that would include response rates and other clinical parameters.
The experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report.
Expanded View for this article is available online.
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The paper explained
Problem
The cancer genome evolves under the selective pressure of targeted
therapies. One of the key challenges is to identify resistance mecha-
nisms and the most dominant drivers as early as possible. Analysis of
plasma cell-free DNA allows one to track molecular dynamics non-
invasively.
Results
This study found that cell-free DNA analysis reveals clinically impor-
tant information during EGFR-targeted therapy in non-small-cell lung
cancer (NSCLC): At baseline, quantitative tumour-derived cell-free DNA
levels in plasma provided prognostic information and correlated with
tumour burden. During treatment, multiple potential indications of
resistance such as EGFR T790M or TP53 can be detected in plasma
months before disease progression became clinically evident. Longitu-
dinal analysis of tumour-derived cell-free DNA levels tracks tumour
responses and reveals heterogeneous resistance mechanisms: The
majority depend on the EGFR pathway while a small subset devel-
oped alterative drivers that could be identified by tracking multiple
mutations in plasma DNA. In patients who developed resistance by
transforming to small-cell lung cancer (SCLC), we identified TP53
mutations, one of the key drivers of SCLC, and SCLC-specific copy
number events in plasma before the transformation.
Impact
Parallel analysis of multiple mutations and copy number alterations
in plasma allows identification of dominant drivers at any given time
during treatment. Tracking EGFR mutations alone in plasma during
EGFR-targeted therapy may not accurately reflect tumour burden due
to underlying tumour heterogeneity. The results of this study provide
important insight about the implication of cell-free DNA analysis for
management of targeted therapies.
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